TEVA
Teva Pharmaceutical Industries Limited NYSE Listed Feb 16, 1982$36.02
After hrs
$35.72
-0.03%
Mkt Cap $41.9B
52w Low $14.99
94.1% of range
52w High $37.35
50d MA $31.36
200d MA $26.17
P/E (TTM)
28.4x
EV/EBITDA
15.8x
P/B
5.1x
Debt/Equity
2.2x
ROE
19.0%
P/FCF
31.2x
RSI (14)
—
ATR (14)
—
Beta
0.76
50d MA
$31.36
200d MA
$26.17
Avg Volume
7.3M
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
124 Dvora Hanevi'a Street · Tel Aviv 6944020 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 0.50 | 0.53 | +6.0% | 35.38 | +1.8% | -0.9% | -1.2% | -0.1% | +1.4% | +2.7% | — |
| Jan 28, 2026 | TNS | 0.65 | 0.96 | +47.7% | 33.21 | +0.2% | -0.4% | +2.6% | +7.0% | +9.2% | +5.3% | — |
| Nov 5, 2025 | TNS | 0.68 | 0.78 | +14.7% | 24.60 | -2.2% | -0.6% | -2.6% | -1.4% | +2.2% | +5.0% | — |
| Jul 30, 2025 | TNS | 0.63 | 0.66 | +4.8% | 16.83 | +0.5% | -8.2% | -8.6% | -6.8% | -6.7% | -4.9% | — |
| May 7, 2025 | TNS | 0.47 | 0.52 | +10.6% | 17.60 | -0.5% | +2.7% | -3.8% | +2.0% | -0.7% | -4.0% | — |
| Jan 29, 2025 | TNS | 0.69 | 0.71 | +2.9% | 18.54 | +0.1% | -3.8% | -4.4% | -6.4% | -8.0% | -7.2% | — |
| Nov 6, 2024 | TNS | 0.65 | 0.69 | +6.2% | 17.43 | +1.1% | +0.4% | -1.8% | -0.3% | -1.8% | -2.8% | — |
| Jul 31, 2024 | TNS | 0.57 | 0.61 | +7.0% | 17.43 | -1.0% | +0.6% | -2.5% | -4.3% | -3.0% | -3.7% | — |
| May 8, 2024 | TNS | 0.51 | 0.48 | -5.9% | 15.74 | -0.2% | +1.7% | +3.2% | +7.2% | +8.6% | +6.6% | — |
| Jan 31, 2024 | TNS | 0.75 | 1.00 | +33.3% | 12.10 | +0.6% | +3.0% | +1.5% | +2.3% | +1.2% | +0.3% | — |
| Nov 8, 2023 | TNS | 0.60 | 0.60 | +0.0% | 9.15 | -0.2% | -4.2% | -5.1% | -3.6% | -2.6% | -2.1% | — |
| Aug 2, 2023 | TNS | 0.54 | 0.56 | +3.7% | 9.25 | -1.3% | +3.5% | +5.5% | +4.1% | +5.7% | +4.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | UBS | Maintains | Buy → Buy | — | $35.38 | $36.02 | +1.8% | -0.9% | -1.2% | -0.1% | +1.4% | +2.7% |
| Apr 30 | JP Morgan | Maintains | Overweight → Overweight | — | $35.38 | $36.02 | +1.8% | -0.9% | -1.2% | -0.1% | +1.4% | +2.7% |
| Apr 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $35.38 | $36.02 | +1.8% | -0.9% | -1.2% | -0.1% | +1.4% | +2.7% |
| Apr 30 | Truist | Maintains | Buy → Buy | — | $35.38 | $36.02 | +1.8% | -0.9% | -1.2% | -0.1% | +1.4% | +2.7% |
| Apr 9 | BofA Securities | Maintains | Buy → Buy | — | $30.52 | $30.45 | -0.2% | +1.4% | +1.0% | +2.1% | +4.1% | +3.6% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.28 | $33.18 | +2.8% | +2.0% | -1.6% | -3.8% | -2.4% | -2.4% |
| Feb 18 | Truist | Maintains | Buy → Buy | — | $34.41 | $34.20 | -0.6% | -0.9% | -0.2% | -0.6% | -1.5% | -1.4% |
| Feb 9 | Goldman Sachs | Maintains | Buy → Buy | — | $34.69 | $34.57 | -0.3% | -0.6% | -0.9% | -1.1% | -2.2% | -2.0% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $33.07 | $32.49 | -1.8% | +3.1% | +7.4% | +9.6% | +5.7% | +5.2% |
| Jan 29 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $33.21 | $33.26 | +0.2% | -0.4% | +2.6% | +7.0% | +9.2% | +5.3% |
| Jan 29 | Truist | Maintains | Buy → Buy | — | $33.21 | $33.26 | +0.2% | -0.4% | +2.6% | +7.0% | +9.2% | +5.3% |
| Jan 6 | Jefferies | Maintains | Buy → Buy | — | $31.00 | $31.63 | +2.0% | +3.6% | +4.5% | +4.9% | +3.3% | +5.8% |
| Dec 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.35 | $30.72 | +1.2% | +2.8% | +3.9% | +4.6% | +5.1% | +4.0% |
| Dec 19 | Goldman Sachs | Maintains | Buy → Buy | — | $30.32 | $30.10 | -0.7% | +0.1% | +2.9% | +4.0% | +4.7% | +5.2% |
| Dec 16 | JP Morgan | Maintains | Overweight → Overweight | — | $30.13 | $30.13 | +0.0% | -0.1% | -0.2% | +0.6% | +0.7% | +3.5% |
| Dec 9 | BofA Securities | Maintains | Buy → Buy | — | $28.33 | $29.07 | +2.6% | +0.8% | +5.2% | +6.5% | +5.2% | +6.4% |
| Dec 8 | Goldman Sachs | Maintains | Buy → Buy | — | $28.46 | $28.74 | +1.0% | -0.5% | +0.4% | +4.7% | +6.0% | +4.7% |
| Nov 6 | JP Morgan | Maintains | Overweight → Overweight | — | $24.60 | $24.05 | -2.2% | -0.6% | -2.6% | -1.4% | +2.2% | +5.0% |
| Oct 3 | JP Morgan | Maintains | Overweight → Overweight | — | $20.05 | $20.17 | +0.6% | -0.2% | -0.4% | +0.1% | +0.8% | -0.0% |
| Sep 24 | UBS | Maintains | Buy → Buy | — | $19.45 | $19.45 | +0.0% | -0.9% | -5.6% | -5.7% | -1.4% | +3.9% |
| Jun 26 | UBS | Maintains | Buy → Buy | — | $17.00 | $17.00 | +0.0% | -2.6% | -1.4% | -1.4% | -2.1% | +0.3% |
| May 12 | JP Morgan | Upgrade | Neutral → Overweight | — | $16.93 | $17.25 | +1.9% | +6.1% | +3.2% | -0.2% | -0.4% | +0.1% |
| May 8 | BofA Securities | Maintains | Buy → Buy | — | $17.60 | $17.52 | -0.5% | +2.7% | -3.8% | +2.0% | -0.7% | -4.0% |
| Mar 6 | BofA Securities | Maintains | Buy → Buy | — | $15.90 | $15.58 | -2.0% | -3.5% | -3.4% | -7.7% | +1.3% | +3.6% |
| Jan 30 | UBS | Maintains | Buy → Buy | — | $18.54 | $18.56 | +0.1% | -3.8% | -4.4% | -6.4% | -8.0% | -7.2% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $18.54 | $18.56 | +0.1% | -3.8% | -4.4% | -6.4% | -8.0% | -7.2% |
| Jan 23 | UBS | Maintains | Buy → Buy | — | $22.01 | $22.01 | +0.0% | -1.0% | -1.5% | -1.0% | -2.2% | -15.8% |
| Jan 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.68 | $21.49 | -0.9% | +1.1% | +0.6% | +1.5% | +0.5% | +0.0% |
| Dec 18 | Barclays | Maintains | Overweight → Overweight | — | $20.88 | $20.45 | -2.1% | +1.5% | +2.1% | +5.8% | +6.4% | +7.4% |
| Oct 23 | Barclays | Maintains | Overweight → Overweight | — | $18.38 | $18.40 | +0.1% | +0.2% | -0.7% | -2.6% | -0.1% | +0.3% |
| Oct 21 | JP Morgan | Maintains | Neutral → Neutral | — | $17.95 | $18.04 | +0.5% | +1.3% | +2.4% | +2.6% | +1.7% | -0.3% |
| Sep 3 | UBS | Maintains | Buy → Buy | — | $18.87 | $18.63 | -1.3% | -1.9% | +0.5% | -2.3% | -4.2% | -5.7% |
| Aug 1 | Barclays | Maintains | Overweight → Overweight | — | $17.43 | $17.25 | -1.0% | +0.6% | -2.5% | -4.3% | -3.0% | -3.7% |
| Jul 10 | UBS | Maintains | Buy → Buy | — | $15.81 | $16.20 | +2.5% | +7.4% | +8.2% | +9.3% | +8.0% | +5.3% |
| Jun 27 | Jefferies | Maintains | Buy → Buy | — | $16.25 | $16.50 | +1.5% | +0.1% | +0.0% | +0.6% | +1.8% | +3.5% |
| Jun 5 | Barclays | Maintains | Overweight → Overweight | — | $16.63 | $16.75 | +0.7% | +1.5% | -0.1% | +1.1% | +1.3% | +4.3% |
| May 30 | BofA Securities | Maintains | Buy → Buy | — | $16.45 | $16.52 | +0.4% | +2.7% | +2.9% | +3.2% | +1.1% | +2.6% |
| May 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.25 | $16.30 | +0.3% | +3.9% | +5.2% | +3.3% | +0.3% | +0.2% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $15.74 | $15.71 | -0.2% | +1.7% | +3.2% | +7.2% | +8.6% | +6.6% |
| Mar 8 | JP Morgan | Upgrade | Underweight → Neutral | — | $13.71 | $13.69 | -0.1% | -0.7% | -2.6% | -1.6% | -0.4% | -1.5% |
| Feb 12 | Piper Sandler | Upgrade | Neutral → Overweight | — | $12.01 | $12.49 | +4.0% | +7.5% | +7.6% | +9.7% | +9.9% | +8.4% |
| Feb 5 | Barclays | Maintains | Overweight → Overweight | — | $12.28 | $12.27 | -0.1% | +0.8% | -0.2% | -1.1% | -1.5% | -2.2% |
| Feb 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.28 | $12.27 | -0.1% | +0.8% | -0.2% | -1.1% | -1.5% | -2.2% |
| Jan 29 | Barclays | Maintains | Overweight → Overweight | — | $11.91 | $11.86 | -0.4% | -0.7% | -1.5% | +1.6% | +4.6% | +3.1% |
| Jan 23 | Jefferies | Upgrade | Hold → Buy | — | $11.49 | $11.78 | +2.5% | +4.4% | +4.2% | +3.0% | +3.7% | +3.0% |
| Jan 3 | Piper Sandler | Upgrade | Underweight → Neutral | — | $10.67 | $10.86 | +1.8% | +2.6% | +2.0% | +6.2% | +7.5% | +6.8% |
| Nov 27 | UBS | Upgrade | Neutral → Buy | — | $9.55 | $9.82 | +2.8% | +3.5% | +2.6% | +1.5% | +2.8% | +1.7% |
| Sep 20 | UBS | Maintains | Neutral → Neutral | — | $10.29 | $10.38 | +0.9% | +4.0% | +0.5% | +0.6% | -0.4% | -0.7% |
| Sep 8 | BofA Securities | Maintains | Buy → Buy | — | $9.35 | $9.41 | +0.6% | +2.9% | +7.4% | +7.3% | +10.5% | +12.9% |
| Jul 6 | UBS | Upgrade | Sell → Neutral | — | $7.49 | $7.52 | +0.4% | +4.5% | +6.3% | +5.5% | +8.5% | +7.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | Weiss Amir | Chief Accounting Officer | Sell | 10,679 | $36.00 | $384K | 20,016 | — | — |
| May 5, 2026 | Daniell Richard | EVP, Europe Commercial | Sell | 30,000 | $35.40 | $1.1M | 55,755 | — | — |
| May 1, 2026 | Sabag Mark | See "Remarks" | Sell | 144,180 | $34.99 | $5.0M | 80,760 | +1.44% | — |
| Apr 30, 2026 | Fox Christine | EVP, U.S. Commercial | Sell | 21,258 | $35.31 | $751K | 63,647 | +1.44% | — |
No recent filings available.
Data updated apr 27, 2026 4:30am
· Source: massive.com